PT  - JOURNAL ARTICLE
AU  - Fadista, João
AU  - Kraven, Luke M.
AU  - Karjalainen, Juha
AU  - Andrews, Shea J.
AU  - Geller, Frank
AU  - ,
AU  - Baillie, J Kenneth
AU  - Wain, Louise V.
AU  - Jenkins, R. Gisli
AU  - Feenstra, Bjarke
TI  - Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity
AID  - 10.1101/2020.12.15.20248279
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.15.20248279
4099  - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20248279.short
4100  - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20248279.full
AB  - Background Idiopathic pulmonary fibrosis (IPF) is a complex lung disease, characterized by progressive lung scarring. Severe COVID-19 is associated with substantial pneumonitis and has a number of shared major risk factors with IPF. This study aimed to determine the genetic correlation between IPF and severe COVID-19 and assess a potential causal role of genetically increased risk of IPF on COVID-19 severity.Methods We performed a Mendelian randomisation (MR) study for IPF causality in COVID-19. Genetic variants associated with IPF susceptibility (P<5×10−8) in previous genome-wide association studies (GWAS) were used as instrumental variables (IVs). Effect estimates of those IVs on COVID-19 severity were gathered from the GWAS meta-analysis by the COVID-19 Host Genetics Initiative. The genetic correlation between IPF and COVID-19 severity was estimated with linkage disequilibrium (LD) score regression.Findings We detected a positive genetic correlation of IPF with COVID-19 severity (rg=0.31 [95% CI 0.04-0.57], P = 0.023). The MR estimates for severe COVID-19 did not reveal any genetic association (OR 1.05, [95% CI 0.92-1.20], P = 0.43). However, outlier analysis revealed that the IPF risk allele rs35705950 at MUC5B had a different effect compared with the other variants. When rs35705950 was excluded, MR results provided evidence that genetically increased risk of IPF has a causal effect on COVID-19 severity (OR 1.21, [95% CI 1.06-1.38], P = 4.24×10−3). Furthermore, the IPF risk-allele at MUC5B showed an apparent protective effect against COVID-19 hospitalization only in older adults (OR 0.86, [95% CI 0.73-1.00], P = 2.99×10−2).Interpretation The strongest genetic determinant of IPF, rs35705950 at MUC5B, seems to confer protection against COVID-19, whereas the combined effect of all other IPF risk loci seem to confer risk of COVID-19 severity. The observed effect of rs35705950 could either be due to protective effects of mucin over-production on the airways or a consequence of selection bias due to a patient group that is heavily enriched for the rs35705950 T undertaking strict self-isolation. Due to the diverse impact of IPF causal variants on SARS-CoV-2 infection, further investigation is needed to address this apparent paradox between variance at MUC5B and other IPF genetic risk factors.Funding Novo Nordisk Foundation and Oak Foundation.Competing Interest StatementLVW receives funding from GSK and Orion, outside of the submitted work. RGJ Jenkins reports personal fees and other from Biogen, personal fees from Galapagos, other from Galecto, personal fees and other from GlaxoSmithKline, personal fees from Heptares, personal fees and other from MedImmune, personal fees from Boehringer Ingelheim, personal fees from Pliant, personal fees from Roche/InterMune, personal fees from MedImmune, personal fees from PharmAkea, personal fees from Bristol Myers Squibb, personal fees from Chiesi, personal fees from Roche/Promedior, other from RedX, other from NuMedii, other from Nordic Biosciences, outside the submitted work; and RGJ is supported by a National Institute of Health Research Professorship (NIHR ref: RP-2017-08-ST2-014). RGJ is a trustee for Action for Pulmonary Fibrosis.Funding StatementJF and BF received partial support from the Novo Nordisk Foundation (NNF18OC0053228) and the Oak Foundation (OCAY-18-598). LVW holds a GSK/British Lung Foundation Chair in Respiratory Research. The research was partially supported by the NIHR Leicester Biomedical Research Centre and the NIHR Nottingham Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. LMK holds a Medical Research Council IMPACT studentship (MR/N013913/1). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Covid-19 HGI and the IPF GWAS consortia have ethical approvals from their respective cohorts [14,15,22]. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupporting data is available in Supplementary Material, on https://www.covid19hg.org/results/ and https://github.com/genomicsITER/PFgenetics. ttps://www.covid19hg.org/results/ https://github.com/genomicsITER/PFgenetics